Effectiveness and Safety of Myval Versus Other Transcatheter Valves in Patients Undergoing TAVI: A Meta-Analysis.

Catheter Cardiovasc Interv · 2025 · PMC12336787 · PMID 40421696

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

LANDMARK trial showed a numerical trend in favor of Myval, without reaching significance, as it was not properly powered for this comparison [ 20 ].

also in 586 other papers

borderline significantno p-value reported

By performing sensitivity analysis using a leave‐one‐out approach, device success becomes non‐significant when we exclude EVAL or TRITON and significant when we remove LANDMARK, early safety borderline significant when we exclude Delgado‐Arena et al. 30‐day minor vascular complications its significance when we remove either Delgado‐Arena et al., EVAL or TRITON, and 30‐day at least moderate AR its significance when we remove all the pooled studies, except LANDMARK.

also in 3,746 other papers

showed a trendno p-value reported

Our analysis showed a trend in favor of Myval regarding successful implantation and this could be attributed to the unique design characteristics of the Myval THV, including its low‐profile, extremely flexible and steerable delivery system, enhanced radial strength, improved deployment mechanism, and ability to adapt to different anatomies.

also in 24,539 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.